CN107073075A - 用于预防或治疗以异常的成纤维细胞增殖和细胞外基质沉积为特征的疾病、病况或进程的组合物和方法 - Google Patents

用于预防或治疗以异常的成纤维细胞增殖和细胞外基质沉积为特征的疾病、病况或进程的组合物和方法 Download PDF

Info

Publication number
CN107073075A
CN107073075A CN201580058532.3A CN201580058532A CN107073075A CN 107073075 A CN107073075 A CN 107073075A CN 201580058532 A CN201580058532 A CN 201580058532A CN 107073075 A CN107073075 A CN 107073075A
Authority
CN
China
Prior art keywords
polypeptide
seq
kinase
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580058532.3A
Other languages
English (en)
Chinese (zh)
Inventor
C.兰德
C.布罗菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moerae Matrix Inc
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of CN107073075A publication Critical patent/CN107073075A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
CN201580058532.3A 2014-08-29 2015-08-28 用于预防或治疗以异常的成纤维细胞增殖和细胞外基质沉积为特征的疾病、病况或进程的组合物和方法 Pending CN107073075A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/473339 2014-08-29
US14/473,339 US9890200B2 (en) 2011-04-12 2014-08-29 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
PCT/US2015/047390 WO2016033432A1 (en) 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (1)

Publication Number Publication Date
CN107073075A true CN107073075A (zh) 2017-08-18

Family

ID=52583553

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580058532.3A Pending CN107073075A (zh) 2014-08-29 2015-08-28 用于预防或治疗以异常的成纤维细胞增殖和细胞外基质沉积为特征的疾病、病况或进程的组合物和方法

Country Status (12)

Country Link
US (2) US9890200B2 (enExample)
EP (1) EP3185883A4 (enExample)
JP (1) JP2017528454A (enExample)
KR (1) KR20170044171A (enExample)
CN (1) CN107073075A (enExample)
AU (1) AU2015308761A1 (enExample)
BR (1) BR112017003731A2 (enExample)
CA (1) CA2958085A1 (enExample)
MX (1) MX2017002476A (enExample)
RU (1) RU2017110093A (enExample)
SG (1) SG11201701135WA (enExample)
WO (1) WO2016033432A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2016112292A1 (en) 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
CN107921082A (zh) * 2015-03-12 2018-04-17 莫伊莱麦屈克斯公司 含有mk2抑制剂肽的组合物用于治疗非小细胞肺癌的用途
CN112920256B (zh) * 2019-11-21 2022-08-19 上海医药工业研究院 一种治疗哮喘的生物肽及其应用
KR20240134978A (ko) 2022-01-14 2024-09-10 상하이 한서 바이오메디컬 컴퍼니 리미티드 피리딘 함유 폴리시클릭 유도체, 이의 제조 방법 및 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120263680A1 (en) * 2011-04-12 2012-10-18 Moerae Matrix, Inc. Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix Deposition

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
LU85034A1 (fr) 1982-10-08 1985-06-19 Glaxo Group Ltd Dispositifs en vue d'administrer des medicaments a des patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DE69333955D1 (de) 1992-04-24 2006-02-02 Stanford Res Inst Int Targeting homologer sequenzen in eukaryotenzellen
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0733059T3 (da) 1993-12-09 2000-10-16 Univ Jefferson Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler
DE69508568T2 (de) * 1994-02-17 1999-10-21 American Home Products Corp., Madison Substituierte biphenyl-derivate mit phosphodiesterase inhibierender wirkung
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
PT1165050E (pt) 1999-04-05 2006-06-30 Mannkind Corp Processos para formacao de po fino
EP1808438B1 (en) 1999-06-29 2014-10-01 MannKind Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
MXPA04010560A (es) 2002-04-25 2005-08-15 Scripps Research Inst Tratamiento y prevencion de condiciones pulmonares.
MY151032A (en) 2002-07-19 2014-03-31 Abbott Lab S A Treatment of tnf? related disorders
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
CA2575684A1 (en) 2004-08-23 2006-03-02 Mannkind Corporation Pulmonary delivery of inhibitors of phosphodiesterase type 5
WO2007033372A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
RU2008142388A (ru) * 2006-04-03 2010-05-10 Тева Фармасьютикл Индастриес Лтд. (Il) Микрочастицы лекарственного вещества
WO2008085191A1 (en) 2007-01-10 2008-07-17 Purdue Research Fundation Polypeptide inhibitors of hsp27 kinase and uses therefor
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
US8063094B2 (en) 2007-02-08 2011-11-22 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
KR101779616B1 (ko) 2008-12-10 2017-09-18 퍼듀 리서치 파운데이션 키나아제의 세포-침투성 펩티드-기초된 저해물질
EP2575855A4 (en) 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120263680A1 (en) * 2011-04-12 2012-10-18 Moerae Matrix, Inc. Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix Deposition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAGDALENA M等: ""MK2 controls the level of negative feedback in the NF-κB pathway and is essential for vascular permeability and airway infl ammation"", 《THE JOURNAL OF EXPERIMENTAL MEDICINE》 *
张克义等: "《临床药物不良反应大典》", 30 September 2001 *

Also Published As

Publication number Publication date
BR112017003731A2 (pt) 2017-12-05
US9890200B2 (en) 2018-02-13
JP2017528454A (ja) 2017-09-28
MX2017002476A (es) 2017-08-14
WO2016033432A1 (en) 2016-03-03
CA2958085A1 (en) 2016-03-03
AU2015308761A1 (en) 2017-02-23
EP3185883A1 (en) 2017-07-05
RU2017110093A3 (enExample) 2018-10-01
WO2016033432A9 (en) 2016-04-21
US10562947B2 (en) 2020-02-18
US20150064134A1 (en) 2015-03-05
SG11201701135WA (en) 2017-03-30
US20180194817A1 (en) 2018-07-12
RU2017110093A (ru) 2018-10-01
KR20170044171A (ko) 2017-04-24
EP3185883A4 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
DK2696888T3 (en) COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF PULMONAL FIBROSE
US10500249B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US10562947B2 (en) Compositions and methods for preventing or treating diseases, conditions or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CN106456758A (zh) 用于预防或治疗慢性肺同种异体移植机能障碍和特发性肺纤维化的组合物和方法
HK1194983B (en) Compositions and methods for preventing or treating pulmonary fibrosis
NZ616672B2 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818